Detail akcie Telomir Pharma Rg online

Business Summary: Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Telomir Pharmaceuticals Inc revenues was not reported. Net loss decreased 39% to $8.4M. Lower net loss reflects Interest expense decrease of 100% to $1K (expense), Research and development expenses decrease of 42% to $1.1M (expense), Related party travel costs decrease from $371K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.46 to -$0.28.